menu

CME: Bringing Bipolar I to Light: Connecting on Diagnosis & Treatment Challenges

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Bringing Bipolar I to Light: Connecting on Diagnosis & Treatment Challenges

close
1.00 credits
60 minutes

CME/CE Broadcast Replay

Bringing Bipolar I to Light: Connecting on Diagnosis & Treatment Challenges
Restart
Resume
Read full article
Choose a format
Get your free creditsSkip straight to the post-test if you have already participated in this activity
Media formats available:
Details
Presenters
Related
Comments
  • Overview

    Bipolar I disorder can be challenging to diagnose and treat. To address these challenges, three faculty experts came together during Mental Illness Awareness Week to discuss key issues in bipolar I disorder care. In this 60-minute activity previously aired as a live broadcast, the faculty discuss how you can overcome challenges in diagnosis and treatment adherence. Further, they utilize lecture, discussion, and debate to help you individualize treatment and discuss long-acting injectable (LAI) antipsychotics based on the evidence.

    Please click here to download the Therapy Decision Tool.

  • Disclosure of Conflicts of Interest

    Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below as they were at the launch of this activity.

    *The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.

    The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity:

    • Planners (Forefront Collaborative): Leah Johnson and Valerie Siclari, PhD
    • Faculty Presenter: Amy Becher-Smith, DNP, MSW, PMHNP-BC, FNP-BC
    • Faculty Planners: Barbara Jones Warren, PhD, RN, APRN, PMHCNS-BC, FNAP, FAAN and James Edgar Skye

    The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:

    Faculty Presenter: Roger S. McIntyre, MD, FRCPC

    • Consultant: Allergan, Janssen, Lundbeck, Minerva, Neurocrine, Otsuka, Pfizer, Purdue, Shire, Sunovion, and Takeda
    • Speakers Bureau: Allergan, Janssen, Lundbeck, Minerva, Neurocrine, Otsuka, Pfizer, Purdue, Shire, Sunovion, and Takeda
    • Research or Grants From Private Industries or Nonprofit Funds: Stanley Medical Research Institute CIHR/GACD/National Natural Science Foundation of China

    Faculty Presenter: Joseph F. Goldberg MD, MS

    • Royalties: American Psychiatric Publishing and Cambridge University Press
    • Consultant: BioXcel, Otsuka, Neurocrine, Sage Pharmaceuticals, and Sunovion
    • Speakers Bureau: AbbVie, Intracellular Therapies, and Sunovion
    • Advisory Boards: Neurocrine, Otsuka, and Sunovion
  • CME Content Review

    The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative and Otsuka America Pharmaceutical, Inc. and Lundbeck.  

    The content of this activity was independently peer reviewed by two reviewers. The reviewers of this activity have no relevant financial relationships to disclose. 

    This continuing medical education activity will include reference(s) to unlabeled or unapproved uses of drugs or devices. 

  • Target Audience

    This activity is designed for psychiatrists, psychiatric/mental health nurse practitioners (NPs) and physician assistants (PAs), and other healthcare professionals (HCPs) who treat patients with bipolar I disorder.

  • Learning Objectives

    Upon completion of this activity, participants should increase their ability to

    1. Diagnose bipolar I disorder earlier in patients. 
    2. Develop individual, evidence-based management plans for patients with bipolar I disorder. 
    3. Discuss LAI antipsychotics as a treatment option for appropriate patients with bipolar I disorder. 
    4. Implement the latest strategies to improve patient adherence to bipolar I disorder treatment regimens
  • Accreditation and Credit Designation Statements

    Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Forefront Collaborative designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    This activity is provided by Forefront Collaborative. 

  • Commercial Support

    This activity is supported by an educational grant from Otsuka America Pharmaceutical, Inc. and Lundbeck.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    Bipolar I disorder can be challenging to diagnose and treat. To address these challenges, three faculty experts came together during Mental Illness Awareness Week to discuss key issues in bipolar I disorder care. In this 60-minute activity previously aired as a live broadcast, the faculty discuss how you can overcome challenges in diagnosis and treatment adherence. Further, they utilize lecture, discussion, and debate to help you individualize treatment and discuss long-acting injectable (LAI) antipsychotics based on the evidence.

    Please click here to download the Therapy Decision Tool.

  • Disclosure of Conflicts of Interest

    Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below as they were at the launch of this activity.

    *The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.

    The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity:

    • Planners (Forefront Collaborative): Leah Johnson and Valerie Siclari, PhD
    • Faculty Presenter: Amy Becher-Smith, DNP, MSW, PMHNP-BC, FNP-BC
    • Faculty Planners: Barbara Jones Warren, PhD, RN, APRN, PMHCNS-BC, FNAP, FAAN and James Edgar Skye

    The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:

    Faculty Presenter: Roger S. McIntyre, MD, FRCPC

    • Consultant: Allergan, Janssen, Lundbeck, Minerva, Neurocrine, Otsuka, Pfizer, Purdue, Shire, Sunovion, and Takeda
    • Speakers Bureau: Allergan, Janssen, Lundbeck, Minerva, Neurocrine, Otsuka, Pfizer, Purdue, Shire, Sunovion, and Takeda
    • Research or Grants From Private Industries or Nonprofit Funds: Stanley Medical Research Institute CIHR/GACD/National Natural Science Foundation of China

    Faculty Presenter: Joseph F. Goldberg MD, MS

    • Royalties: American Psychiatric Publishing and Cambridge University Press
    • Consultant: BioXcel, Otsuka, Neurocrine, Sage Pharmaceuticals, and Sunovion
    • Speakers Bureau: AbbVie, Intracellular Therapies, and Sunovion
    • Advisory Boards: Neurocrine, Otsuka, and Sunovion
  • CME Content Review

    The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative and Otsuka America Pharmaceutical, Inc. and Lundbeck.  

    The content of this activity was independently peer reviewed by two reviewers. The reviewers of this activity have no relevant financial relationships to disclose. 

    This continuing medical education activity will include reference(s) to unlabeled or unapproved uses of drugs or devices. 

  • Target Audience

    This activity is designed for psychiatrists, psychiatric/mental health nurse practitioners (NPs) and physician assistants (PAs), and other healthcare professionals (HCPs) who treat patients with bipolar I disorder.

  • Learning Objectives

    Upon completion of this activity, participants should increase their ability to

    1. Diagnose bipolar I disorder earlier in patients. 
    2. Develop individual, evidence-based management plans for patients with bipolar I disorder. 
    3. Discuss LAI antipsychotics as a treatment option for appropriate patients with bipolar I disorder. 
    4. Implement the latest strategies to improve patient adherence to bipolar I disorder treatment regimens
  • Accreditation and Credit Designation Statements

    Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Forefront Collaborative designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    This activity is provided by Forefront Collaborative. 

  • Commercial Support

    This activity is supported by an educational grant from Otsuka America Pharmaceutical, Inc. and Lundbeck.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 12/3/20